Gilead Sciences, Inc. (NASDAQ:GILD) Stake Boosted by Fiduciary Trust Co

Fiduciary Trust Co boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 26.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,424 shares of the biopharmaceutical company’s stock after purchasing an additional 2,807 shares during the quarter. Fiduciary Trust Co’s holdings in Gilead Sciences were worth $1,125,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Cetera Investment Advisers increased its holdings in shares of Gilead Sciences by 127.6% in the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock worth $15,668,000 after acquiring an additional 119,909 shares during the period. Cetera Advisors LLC grew its position in Gilead Sciences by 167.2% in the 1st quarter. Cetera Advisors LLC now owns 82,786 shares of the biopharmaceutical company’s stock worth $6,064,000 after purchasing an additional 51,801 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Gilead Sciences by 56.0% in the second quarter. GAMMA Investing LLC now owns 9,940 shares of the biopharmaceutical company’s stock valued at $682,000 after purchasing an additional 3,567 shares during the period. Massmutual Trust Co. FSB ADV raised its holdings in shares of Gilead Sciences by 72.6% during the second quarter. Massmutual Trust Co. FSB ADV now owns 4,487 shares of the biopharmaceutical company’s stock valued at $308,000 after buying an additional 1,887 shares during the last quarter. Finally, Modus Advisors LLC raised its holdings in shares of Gilead Sciences by 10.8% during the second quarter. Modus Advisors LLC now owns 9,810 shares of the biopharmaceutical company’s stock valued at $673,000 after buying an additional 960 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 0.2 %

Gilead Sciences stock opened at $92.58 on Friday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market capitalization of $115.38 billion, a price-to-earnings ratio of 1,028.67, a P/E/G ratio of 2.87 and a beta of 0.17. The company has a 50 day moving average price of $88.26 and a 200 day moving average price of $77.69.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 earnings per share. Research analysts forecast that Gilead Sciences, Inc. will post 4.37 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. The Goldman Sachs Group raised their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Robert W. Baird raised their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Barclays increased their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Finally, UBS Group boosted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Twelve analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.41.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 227,946 shares of company stock worth $20,683,305. 0.16% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.